About UCB, Inc.
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).
244 articles with UCB, Inc.
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.
New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
Survey reveals that women of childbearing age with chronic rheumatic diseases experience unique challenges, and suggests many experience a lack of guidance and consistent information regarding family planning and treatment during their pregnancy journey and breastfeeding
Quebecers Living with Advanced Parkinson's Disease Now Have Broader Access to NEUPRO (rotigotine) As Add-On Therapy
UCB Canada Inc. announced today that Quebecers now have publicly funded access (special authorization) to NEUPRO® (rotigotine) for the treatment of advanced stage Parkinson's Disease (APD), in combination with the drug levodopa.
Canadians Living with Advanced Parkinson's Disease Now Have Broader Access to NEUPRO (rotigotine) As Add-On Therapy
UCB Canada Inc. announced that NEUPRO® (rotigotine) is now available through public funding (special authorization) all across Canada*, in combination with the drug levodopa for the treatment of patients with advanced stage Parkinson's Disease (APD).
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA® (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
UCB today announced positive topline results from C-AXSPAND, a Phase 3 placebo controlled study to investigate the efficacy of CIMZIA® (certolizumab pegol) on the signs and symptoms of active axSpA in patients without x-ray evidence of ankylosing spondylitis (AS).
UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients
BRIVIACT CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures
Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home
Science 37 announced a strategic collaboration with global pharmaceutical leader, UCB, to improve the clinical trial experience.
UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off
Acquisition to strengthen UCB's genomics and epigenomics research platform to identify novel drug targets
CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.
UCB announced today that the U.S. Food and Drug Administration (FDA) approved a label update that includes pharmacokinetic data showing negligible to low transfer of CIMZIA® (certolizumab pegol) through placenta and minimal transfer to breast milk from mother to infant.
This month, UCB, Inc.’s Vice President for U.S. Corporate Affairs, Patricia A. Fritz, was elected chair of Georgia Bio’s Board of Directors for the 2018-2019 term.
Syndesi will work to modulate the synaptic vesicle protein SV2A.
UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting
Study findings suggest that opioids are vastly overprescribed as a treatment for pain associated with AS, often in lieu of more effective treatments such as anti-TNFs and NSAIDs.
UCB's VIMPAT (lacosamide) Now Approved by FDA to Treat Partial-Onset Seizures in Pediatric Epilepsy Patients
This new approval provides clinicians with the option to prescribe VIMPAT to their pediatric patients either as an oral solution or a convenient tablet.
UCB, Inc. Release: Results From CRIB Study On CIMZIA (Certolizumab Pegol) Demonstrate Minimal To No Placental Transfer Of Drug From Mother To Infant During Third Trimester Of Pregnancy
UCB, Inc. Selects Medidata Solutions, Inc. Clinical Cloud To Support Patient-Centric Drug Development
UCB, Inc. Release: First CIMZIA (Certolizumab Pegol) Study Of Its Kind Showed Minimal To No Transfer Of Drug From Mother's Plasma To Breast Milk